Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
1. FDA warned Hims & Hers over misleading claims on compounded semaglutide products. 2. FDA's warning targets unlawful sales of unapproved drugs online. 3. Hims & Hers shares dropped nearly 6% after receiving the letter. 4. FDA crackdown follows Trump's order on drug advertising regulations. 5. Hims & Hers stock is still up 12.7% this month despite decline.